4.6 Article

Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies

期刊

GENETICS IN MEDICINE
卷 23, 期 3, 页码 451-460

出版社

SPRINGERNATURE
DOI: 10.1038/s41436-020-01012-w

关键词

developmental disabilities; multiple congenital anomalies; cost-effectiveness; genome-wide sequencing

资金

  1. Canada Research Chair in Economic Evaluation and Technology Assessment in Child Health
  2. Canada Research Chair in Rare Disease Precision Health

向作者/读者索取更多资源

Genetic testing plays a crucial role in addressing unexplained developmental disabilities and multiple congenital anomalies. Comprehensive sequencing can improve diagnosis but comes with higher cost. The study suggests that utilizing ES earlier in the diagnostic pathway may be cost-saving.
Purpose Genetic testing is routine practice for individuals with unexplained developmental disabilities and multiple congenital anomalies. However, current testing pathways can be costly and time consuming, and the diagnostic yield low. Genome-wide sequencing, including exome sequencing (ES) and genome sequencing (GS), can improve diagnosis, but at a higher cost. This study aimed to assess the cost-effectiveness of genome-wide sequencing in Ontario, Canada. Methods A cost-effectiveness analysis was conducted using a discrete event simulation from a public payer perspective. Six strategies involving ES or GS were compared. Outcomes reported were direct medical costs, number of molecular diagnoses, number of positive findings, and number of active treatment changes. Results If ES was used as a second-tier test (after the current first-tier, chromosomal microarray, fails to provide a diagnosis), it would be less costly and more effective than standard testing (CAN$6357 [95% CI: 6179-6520] vs. CAN$8783 per patient [95% CI: 2309-31,123]). If ES was used after standard testing, it would cost an additional CAN$15,228 to identify the genetic diagnosis for one additional patient compared with standard testing. The results remained robust when parameters and assumptions were varied. Conclusion ES would likely be cost-saving if used earlier in the diagnostic pathway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据